Piśmiennictwo:
1. Quigley EMM, Craig OF. Irritable bowel syndrome; update on pathophysiology and management. Turk J Gastroenterol 2012;23(4):313-22.
2. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology 2006;130:1377-90.
3. Martínez C, González-Castro A, Vicario M, et al. Cellular and molecular masis of intestinal barrier dysfunction in the irritable bowel syndrome. Gut and Liver 2012;6(3):305-15.
4. Tomecki R. Zespół jelita nadwrażliwego. Program edukacyjny dla lekarzy. Gdańsk: VM Media Sp.z o.o., 2006.
5. Maxion-Bergemann S, Thielecke F, Abel F, et al. Costs of irritable bowel syndrome in the UK and US. Pharmacoeconomics 2006;24:21-37.
6. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002;97:1910-5.
7. Choroby czynnościowe przewodu pokarmowego. Wytyczne rzymskie III. Medycyna Praktyczna 2007;8(wyd. spec.):28-35.
8. Wang A, Liao X, Xiong L, et al. The clinical overlap between functional dyspepsia and irritable bowel syndrome based on Rome III criteria. BMC Gastroenterol 2008;8:43.
9. Whitehead WE, Palsson O, Jones KR. Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications? Gastroenterology 2002;122:1140-56.
10. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303(7):G775-85.
11. Trinkley KE, Nahata MC. Leczenie zespołu jelita nadwrażliwego. Gastroenterologia Praktyczna 2011;5(12):6-14.
12. Srinath AI, Walter C, Melissa C, et al. Pain management in patients with inflammatory bowel disease: insights for the clinician. Ther Adv Gastroenterol 2012;5(5):339-57.
13. Kraneveld AD, Rijnierse A, Nijkamp FP, et al. Neuro-immune interactions in inflammatory bowel disease and irritable bowel syndrome: future therapeutic targets. Eur J Pharmacol 2008;585:361-74.
14. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011;140:91-100.
15. Rajagopalan M, Kurian G, John J. Symptom relief with amitryptyline in the irritable bowel syndrome. Journal of Gastroenterology and Hepatology 1998;13:738-41.
16. Bahar RJ, Collins BS, Steinmetz B, et al. Double-blind, placebo controlled trial of amitryptyline fo the treatment of irritable bowel syndrome in adolescents. Journal of Pediatrics 2008;152:685-9.
17. Vij JG, Jiloha RG, Kumar N, et al. Effect of antidepressant drug (doxepin) on irritable bowel syndrome patients. Indian Journal of Psychiatry 1991;33:243-6.
18. Manocha M, Khan WI. Serotonin and GI disorders: An update on clinical and experimental studies. Clinical and Translational Gastroenterology 2012;3:e13.
19. Masand PS, Pae CU, Krulewicz S, et al. A double-blind, randomized, placebo-controlled trial of paroxetine-controlled-release in irritable bowel syndrome. Psychosomatics 2009;50:78-86.
20. Kuiken SD, Tytgat GNJ, Boeckxstaens GEE. The selective serotonin reuptake inhibitor fluoxetine does not change recital sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clinical Gastroenterology and Hepatology 2003;1:219-28.
21. Tack J, Broekaert D, Fischler B, et al. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut 2006;55:1095-103.
22. Talley NJ, Kellow JE, Boyce P, et al. Antidepressant therapy (imipramine and citalopram) for irritable bowel syndrome: a double-blind, randomized, placebocontrolled trial. Digestive Disease and Sciences 2008;53:108-15.
23. Mulak A, Waszczuk E. Zespół jelita nadwrażliwego. W: Paradowski L. Zaburzenia czynnościowe przewodu pokarmowego. Wrocław: Cornetis, 2007:111.
24. Talley NJ. Evaluation of drug treatment in irritable bowel syndrome. Br J Clin Pharmacol 2003;56:362-9.
25. Olden KW. Targeted therapies for diarrhea-predominant irritable bowel syndrome. Clinical and Experimental Gastroenterology 2012;5:69-100.
26. Evans BW, ClarkWK, MooreDJ, et al. Tegaserod for the treatment of irritable bowel syndrome. Cochrane Database of Systematic Reviews 2004; Issue 1, Art. No.: CD003960.
27. Gomułka WS. Farmakodynamika leków wpływających na czynność przewodu pokarmowego. W: Janiec W. Farmakodynamika – podręcznik dla studentów farmacji. Warszawa: Wydawnictwo Lekarskie PZWL 2008:620.
28. Lee N, Wald A. Linaclotide: evidence for its potential use in irritable bowel syndrome and chronic constipation. Core Evidence 2012:7:39-47.
29. Simren M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation Report. Gut 2013;62:159-76.
30. Roberts LM, McCahon D, Holder R, et al. A randomised controlled trial of a probiotic ‘functional food’ in the management of irritable bowel syndrome BMC. Gastroenterology 2013,13:45.
31. Neubauer K, Kempiński R. Zaparcie i biegunka czynnościowa, W: Paradowski L. Zaburzenia czynnościowe przewodu pokarmowego. Wrocław: Cornetis, 2007:127.
32. Paradowski L. Zespół jelita nadwrażliwego. W: Dąbrowski A. (red.). Wielka Interna. Gastroenterologia. Cz. II. Warszawa: Medical Tribune Polska, 2011:263.